Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9333278 | 1.00 | ALDH1A1 (0.60) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL616408 | 0.98 | — | — | |
| SCHEMBL33420 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL7878546 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL1063406 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL5481930 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL8504058 | 0.86 | ALDH1A1 (0.45) | ALDH1A1TSHRTHRBEPHX2SMN1; SMN2 | |
| SCHEMBL5836410 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL11791637 | 0.86 | ALDH1A1 (0.43) | ALDH1A1TSHRTHRBHSD17B10TP53 | |
| SCHEMBL8506799 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRTHRBHSD17B10EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-21 | — | — | US | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B9 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2020-04-29 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| EP-3290413-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-3290413-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO Pharmaceutical Co., Ltd. (JP) | 2018-03-07 | — | — | EP | disclosed |
| EP-2794597-B1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| EP-0710360-A1 | HOMOGENEOUS IMMUNOASSAYS USING MUTANT GLUCOSE-6-PHOSPHATE DEHYDROGENASES | BEHRINGWERKE Aktiengesellschaft (DE) | 1996-05-08 | — | — | EP | disclosed |
| WO-1996002004-A1 | IMMUNOASSAY FOR MYCOPHENOLIC ACID | BEHRINGWERKE AG (DE) | 1996-01-25 | — | — | WO | disclosed |
| WO-1994024559-A2 | HOMOGENEOUS IMMUNOASSAYS USING MUTANT GLUCOSE-6-PHOSPHATE DEHYDROGENASES | SYNTEX (U.S.A.) INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| US-5350839-A | Esters to improve taste and remove bitterness | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1994-09-27 | — | — | US | disclosed |
| EP-0553353-A1 | 2'-MODIFIED ERYTHROMYCIN OR DERIVATIVE THEREOF | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-4737488-A | Immune system-stimulating N-glycosylated ureas and carbamates | BAYER AKTIENGESELLSCHAFT (DE) | 1988-04-12 | — | — | US | disclosed |
| US-4233401-A | Antienzyme homogeneous competitive binding assay | SYVA COMPANY (US) | 1980-11-11 | — | — | US | disclosed |
| US-4069105-A | FOR ENZYME IMMUNOASSAY AND COMPETITIVE PROTEIN BINDING ASSAY | SYVA COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
| US-4058511-A | Tegretol antigens and antibodies | SYVA COMPANY (US) | 1977-11-15 | — | — | US | disclosed |
| US-3998816-A | 7-[5-N-(n-Butoxyethoxy carbonyl and 2-chloroethoxy carbonyl)-amino] cephalosporins C | MEIJI SEIKA KAISHA, LTD. (JA) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | ALDH1A1 1061/4885TSHR 2426/4885THRB 912/4885 |
| US-10717738-B2 | Pyrimidinone and its derivatives inhibiting factor XIa | F11, TFPI, F10 | ALDH1A1 1823/4885TSHR 3415/4885THRB 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.